-
Post date
April 19, 2022
-
Posted by
Kieran Robertson
-
Posted in
FH.NE, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, filament health neo, Filament Health Trials, filament stock, Mushrooms, Natural Psychedelic, natural psychedelic extraction, natural psychedelics, Patent, patent issue, psilocybin, Psychedelics, Psyence Group, psyg.c
-
Post date
April 12, 2022
-
Posted by
Kieran Robertson
-
Posted in
clinical psychedelics, clinical trials psychedelics, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, filament stock, IND, Mushrooms, pre-ind, psilocybin, psilocybin market, Psychedelics
-
Post date
April 27, 2021
-
Posted by
Lukas Kane
-
Posted in
5 best Canadian Biotechs, Biotech, Biotech collaborations, Bucillamine, Canadian Biotech, cancer treatment, Cannabis, clinical sites, Covid-19 treatment, CRO, CymaBay Therapeutics (CBAY.NASDAQ), Fabio Chianelli, Featured Content, Health Science, Institutional Review Board, Investigational new drug, IRB, Kane, liver disease, massive buying, mushroom, mushroom research, Mushrooms, Novotech, Pharm-Olam LLC, PharmaTher, PharmaTher (PHRM.C), Phase 3 FDA trial, Phase 3 trial, Psychedelics, research, resperitory viral infections, Revive Therapeutics, RVV.C, Scribes, Series, shrooms, stock price surge, undervalued bio tech companies, wealth creation
